Use of alkylated iminosugars to treat multidrug resistance

• US 6,225,325 B1
• Filed: 11/10/1998
• Issued: 05/01/2001
• Est. Priority Date: 11/10/1997
• Status: Expired due to Fees

• Current Assignee: GD Searle LLC (Pfizer Inc.)
• Original Assignee: GD Searle LLC (Pfizer Inc.)
• Inventors: Jacob, Gary S.
• Primary Examiner(s): Jones, Dwayne C.
• Application Number:
  US09/189,177
• Time in Patent Office: 903 Days
• Field of Search: 514/328
• US Class Current: 514/328
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/475 having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine vincamine A61K31/4375
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 211/46 having a hydrogen atom as the second substituent in position 4

Abstract

Methods and compositions for preventing, reducing, or reversing multidrug resistance (MDR) during cancer chemotherapy in patients undergoing treatment with therapeutically effective amounts of chemotherapeutic agents are provided. The methods comprise administering an anti-MDR effective amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol iminosugar to a patient.

Claims

1. A method for preventing, reducing, or reversing multidrug resistance in a patient undergoing treatment with a chemotherapeutic agent, comprising administering to said patient an anti-multidrug resistance effective amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound of Formula I:

wherein R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C₂ to C₂₀, and

W, X, Y and Z are independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl, or

a pharmaceutically acceptable salt thereof,

for a period of time effective to prevent, reduce, or reverse multidrug resistance in cancer cells of said patient.

2. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is administered prior to administration of said chemotherapeutic agent.

3. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is administered both prior to and simultaneously with administration of said chemotherapeutic agent.

4. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is administered prior to, simultaneously with, and subsequently to administration of said chemotherapeutic agent.

5. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is administered prior to and subsequently to administration of said chemotherapeutic agent.

6. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is administered daily throughout the course of treatment with said chemotherapeutic agent.

7. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is administered daily to said patient commencing in a period from about 14 days to about three days prior to administration of said chemotherapeutic agent.

8. The method of claim 7, further comprising administering an effective amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound for a period of time effective to alleviate multidrug resistance effects subsequent to administration of said chemotherapeutic agent.

9. The method of claim 8, wherein said period of time effective to alleviate multidrug resistance effects subsequent to administration of said chemotherapeutic agent is in the range of from about one to about five days after administration of said chemotherapeutic agent.

10. The method of claim 1, wherein said effective amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is administered in a one-third divided subdose every eight hours.

11. The method of claim 1, wherein R is a straight or branched chain alkyl group having a chain length of C₂ to C₂₀, and W, X, Y, and Z are each hydrogen.

12. The method of claim 11, wherein R is a straight chain alkyl group having a chain length of C₄ to C₂₀.

13. The method of claim 12, wherein R is a straight chain alkyl group having a chain length of C₄ to C₁₄.

14. The method of claim 13, wherein R is a straight chain alkyl group having a chain length of C₄ to C₁₀.

15. The method of claim 14, wherein R is a straight chain alkyl group having a chain length of C₄ to C₈.

16. The method of claim 15, wherein R is a straight chain alkyl group having a chain length of C₄ to C₆.

17. The method of claim 16, wherein R is n-butyl.

18. The method of claim 16, wherein R is n-hexyl.

19. The method of claim 1, wherein R is a straight or branched chain alkyl group having a chain length of C₂ to C₂₀, and W, X, Y, and Z are each an alkanoyl group having a chain length of C₁ to C₂₀.

20. The method of claim 19, wherein R is a straight chain alkyl group having a chain length of C₄ to C₂₀.

21. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is selected from the group consisting of:

N-(n-ethyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(n-propyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(n-butyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(n-hexyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(n-heptyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(n-octyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(n-octyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(n-decyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(n-undecyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(n-decyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(n-undecyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(n-dodecyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(6-cyclohexylhexyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(3- (4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol;

N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(n-decyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(n-undecyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(n-dodecyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(7-methyloctyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(8-methylnonyl)-1,S-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(6-cyclohexylhexyl-)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate; and

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, tetrabutyrate, or

a pharmaceutically acceptable salt thereof.

22. The method of claim 21, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is selected from the group consisting of N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol and N-(n-hexyl) -1,5-dideoxy-1,5-imino-D-glucitol or galactitol.

23. The method of claim 1, wherein said chemotherapeutic agent is selected from the group consisting of an alkaloid, a topoisomerase II inhibitor, and a DNA damaging agent.

24. The method of claim 23, wherein said alkaloid is a vinca alkaloid.

25. The method of claim 24, wherein said vinca alkaloid is selected from the group consisting of vincristine, vinblastine, and vindesine.

26. The method of claim 23, wherein said topoisomerase II inhibitor is selected from the group consisting of an anthracycline and an epipodophyllotoxin.

27. The method of claim 26, wherein said anthracycline is selected from the group consisting of doxorubicin, daunorubicin, idarubicin, and mitoxantrone.

28. The method of claim 26, wherein said epipodophyllotoxin is selected from the group consisting of etoposide and tenoposide.

29. The method of claim 23, wherein said DNA damaging agent is actinomycin D.

30. The method of claim 1, wherein said effective amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is an amount that results in a blood serum concentration in the range of from about 5 μ

M to about 500 μ

M by whatever route it is administered.

31. The method of claim 30, wherein said effective amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is an amount that results in a blood serum concentration in the range of from about 20 μ

M to about 60 μ

M by whatever route it is administered.

32. The method of claim 31, wherein said effective amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is an amount that results in a blood serum concentration of about 50 μ

M by whatever route it is administered.

33. The method of claim 1, wherein said effective amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is in the range of from about 10 mg/day to about 3,000 mg/day.

34. The method of claim 33, wherein said effective amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is in the range of from about 100 mg/day to about 3,000 mg/day.

35. The method of claim 34, wherein said effective amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is in the range of from about 1,000 mg/day to about 3,000 mg/day.

36. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is administered orally or parenterally.

37. The method of claim 36, wherein said chemotherapeutic agent is administered parenterally.

38. The method of claim 37, wherein said parenteral administration is by slow intravenous infusion.

40. A pharmaceutical composition, comprising an anti-multidrug resistance effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound of claim 1;

an anti-tumor effective amount of at least one anti-tumor chemotherapeutic compound; and

a pharmaceutically acceptable carrier.

41. The pharmaceutical composition of claim 40, wherein both said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound and said anti-tumor chemotherapeutic compound are in controlled release form.

42. The pharmaceutical composition of claim 40, wherein only said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol or galactitol compound is in controlled release form.

39. A method for preventing, reducing, or reversing multidrug resistance in a patient undergoing treatment with a chemotherapeutic agent selected from the group consisting of an alkaloid, a topoisomerase II inhibitor, an anti-microtubule agent, and a DNA damaging agent, comprising:

administering to said patient about 1,000 mg/day to about 3,000 mg/day of N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol or N-(n-hexyl)-1,5-dideoxy-1,5-imino-D-glucitol or galactitol, or a pharmaceutically acceptable salt thereof,

in three equal subdoses, each of which is administered at eight hour intervals, commencing about 10 days prior to administration of said chemotherapeutic agent, and continuing daily thereafter throughout the course of administration of said chemotherapeutic agent.